Allergan tries to assuage shareholder fears over Restasis
(Reuters) - Allergan Plc on Wednesday tried to reassure shareholders after losing a major patent ruling last month on its second-most important drug, dry-eye treatment Restasis, downplaying the importance of the loss of revenue from the drug. (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Allergan beats earnings estimates on strong sales of Botox, Restasis
(Reuters) - Allergan Plc's third-quarter profit topped Wall Street forecasts on Wednesday, as the drugmaker sold more Botox and benefited from strength in its eye care business that houses dry-eye medicine Restasis. (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
MENTOR Results, New Trial Design Pitches at Kidney Week MENTOR Results, New Trial Design Pitches at Kidney Week
Findings from a randomized comparison of rituximab and cyclosporine for membranous nephropathy will be released here at Kidney Week, along with innovative trial design ideas for the future.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 25, 2017 Category: Consumer Health News Tags: Nephrology News Source Type: news
Imprimis to offer low-cost alternative to Restasis for dry eye disease
Imprimis Pharmaceuticals is set to provide its cyclosporine-based formulations as customisable and potential low-cost alternatives to Restasis indicated for dry eye disease. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 22, 2017 Category: Pharmaceuticals Source Type: news
Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis(R)
Initial prescriptions will be 99 cents for a one month supply with refills starting at $79 per month, including shipping
SAN DIEGO, Oct. 19, 2017 -- (Healthcare Sales & Marketing Network) -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmol... Biopharmaceuticals, Ophthalmology, Product Launch Imprimis Pharmaceuticals, Cyclosporine, Restasis, Dry Eye (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 19, 2017 Category: Pharmaceuticals Source Type: news
Imprimis Pharma to take on Allergan's Restasis with cheaper product
(Reuters) - Shares of Imprimis Pharmaceuticals sky-rocketed as much as 91.1 percent on Thursday, after it said it would offer a cheaper option to Allergan's dry eye disease medicine, Restasis. (Source: Reuters: Health)
Source: Reuters: Health - October 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Allergan ruling casts doubt on tribal patent strategy
(Reuters) - A U.S. judge ’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said. (Source: Reuters: Health)
Source: Reuters: Health - October 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
U.S. Judge in Texas Invalidates Allergan Patents on Restasis U.S. Judge in Texas Invalidates Allergan Patents on Restasis
A U.S. judge invalidated patents on Allergan Plc ' s dry eye medicine Restasis on the grounds that the patents cover obvious ideas, a decision that drove the pharmaceutical company ' s shares down more than 6%.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 17, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Mylan: Allergan ’ s legal move with tribe reveals “ duplicitousness ” towards patent system
Allergan (NYSE:AGN) was dealt a major blow yesterday after a Texas judge ruled that claims to a number of patents for its dry eye drug, Restasis, were invalid due to obviousness. The ruling opens the door for generic versions of the drug that accounted for nearly 10% of Allergan’s revenue last year.
The decision came in a suit involving generic drugmakers like Mylan (NSDQ:MYL), which celebrated the ruling as a push back against Allergan’s recent move to transfer its Restasis patents to a Native American tribe.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan: Allergan’s legal ...
Source: Mass Device - October 17, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Patent Infringement Pharmaceuticals Wall Street Beat Allergan Inc. Mylan Source Type: news
Patents For Restasis Are Invalidated, Opening Door to Generics
The ruling, by a federal judge in Texas, is a setback for Allergan, which had transferred the patents to a Mohawk tribe in order to protect them. (Source: NYT Health)
Source: NYT Health - October 16, 2017 Category: Consumer Health News Authors: KATIE THOMAS Tags: Inventions and Patents Drugs (Pharmaceuticals) Generic Brands and Products Allergan Inc Patent and Trademark Office (US) Source Type: news
Texas judge rules Allergan ’s Restasis patents invalid
U.S. judge William Bryson ruled that patents covering Allergan‘s (NYSE:AGN) Restasis medicine are invalid on the grounds of obviousness, driving the company’s shares down more than -6% in afternoon trading today.
The decision, made in a Texas federal court, is part of an ongoing case between Allergan and generic drugmakers like Mylan (NSDQ:MYL) and Teva Pharmaceuticals (NYSE:TEVA).
Get the full story at our sister site, Drug Delivery Business News.
The post Texas judge rules Allergan’s Restasis patents invalid appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 16, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Legal News Optical/Ophthalmic Patent Infringement Pharmaceuticals Wall Street Beat Allergan Inc. Mylan Teva Pharmaceuticals Source Type: news
U.S. judge in Texas invalidates Allergan patents on Restasis
(Reuters) - Shares of pharmaceutical company Allergan Plc dropped on Monday after a ruling by a U.S. judge invalidated patents on its dry eye medicine Restasis on the grounds that the patents cover obvious ideas. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
MassDevice.com +5 | The top 5 medtech stories for October 13, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. 10 tips for selecting and managing a medtech development partner
There many things to consider when searching for and interacting with a product development firm – and the stakes are high! Most early-stage medical device comp...
Source: Mass Device - October 13, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Allergan settles Restasis patent challenge after moving patents to Native American tribe
Allergan (NYSE:AGN) said yesterday that it inked a deal with InnoPharma to settle a patent challenge over Allergan’s dry eye drug, Restasis.
InnoPharma is one of four companies challenging Allergan’s patents to its eye drop product. The group also includes Mylan (NSDQ:MYL), Teva Pharmaceuticals (NYSE:TEVA) and Akorn Inc. (NSDQ:AKRX) – all of which are challenging the Restasis patents in federal court.
Get the full story at our sister site, Drug Delivery Business News.
The post Allergan settles Restasis patent challenge after moving patents to Native American tribe appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 13, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Optical/Ophthalmic Patent Infringement Pharmaceuticals Wall Street Beat Akorn Allergan Inc. innopharma Mylan Teva Pharmaceuticals Source Type: news
